Daewoong Pharmaceutical Announces U.S. FDA Approval of its IND Application for DWP213388, the First-in-Class Oral, Irreversible, Dual-Acting Antifungal Drug for the Treatment of Autoimmune Diseases

—DWP213388 is the first-in-class dual-target inhibitor that simultaneously inhibits pathogenic T cells and B cells in various autoimmune diseases

SEOUL, South Korea, Aug.

Daewoong Pharmaceutical Announces U.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical, said: "Daewoong Pharmaceutical plans to collaborate with global licensees to lead the development of various new medicines such as DWP213388 for the treatment of autoimmune diseases

The planned Phase I clinical trial is a double-blind, randomized, placebo-controlled, single- and multiple-dose dose-escalation study involving 80 healthy subjects

Unlike current treatments that are generally limited to suppressing B cells or T cells, DWP213388 is a dual-target inhibitor that suppresses both B and T cells, and therefore has greater therapeutic potential than traditional single-acting therapies

The global autoimmune disease treatment market is growing at an average annual rate of 4.

To the editor:

Our body's immune cells interact, directly or indirectly attracting or activating other cells of the immune system

Autoimmune diseases arise when the internal immune system recognizes and attacks normal cells in the body that act as antigens, even though these cells are not foreign antigens such as bacteria and viruses

Source: Daewoong Pharmaceutical Co.